KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $127.3 million.

  • Ionis Pharmaceuticals' Other Non-Current Assets rose 37.95% to $166.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.0 million, marking a year-over-year increase of 37.95%. This contributed to the annual value of $127.3 million for FY2024, which is 20.89% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $127.3 million for FY2024, which was up 20.89% from $105.3 million recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Other Non-Current Assets peaked at $127.3 million during FY2024, and registered a low of $50.0 million during FY2020.
  • Moreover, its 3-year median value for Other Non-Current Assets was $105.3 million (2023), whereas its average is $102.6 million.
  • Data for Ionis Pharmaceuticals' Other Non-Current Assets shows a peak YoY spiked of 81.07% (in 2020) over the last 5 years.
  • Ionis Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $50.0 million in 2020, then spiked by 41.10% to $70.6 million in 2021, then increased by 6.72% to $75.3 million in 2022, then skyrocketed by 39.73% to $105.3 million in 2023, then increased by 20.89% to $127.3 million in 2024.